Matthew W. Onaitis

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA.

Mainstay Medical International Ltd. is a medical device company, which is engages in the development of neurostimulation system. It focuses on the study of ReActiv8, a medical device designed to treat people with chronic low back pain. The company was founded by Danny Sachs in 2008 and is headquartered in San Diego, CA.

Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.

Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA.

Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA.